| Company Name: |
TargetMol Chemicals Inc.
|
| Tel: |
15002134094 |
| Email: |
marketing@targetmol.cn |
| Products Intro: |
Product Name:YQ456
CAS:2093946-08-6
Package:25mg/RMB 10600;100mg/RMB 17500;50mg/RMB 13800
|
Benzamide, 3-[3-ethyl-5-(4-methoxyphenyl)-1H-1,2,4-triazol-1-yl]-N-(4-phenylbutyl)- manufacturers
- YQ456
-
- $1520.00 / 25mg
-
2024-11-19
- CAS:2093946-08-6
- Min. Order:
- Purity:
- Supply Ability: 10g
|
| | Benzamide, 3-[3-ethyl-5-(4-methoxyphenyl)-1H-1,2,4-triazol-1-yl]-N-(4-phenylbutyl)- Basic information |
| | Benzamide, 3-[3-ethyl-5-(4-methoxyphenyl)-1H-1,2,4-triazol-1-yl]-N-(4-phenylbutyl)- Chemical Properties |
| density | 1.14±0.1 g/cm3(Predicted) | | pka | 14.20±0.46(Predicted) |
| | Benzamide, 3-[3-ethyl-5-(4-methoxyphenyl)-1H-1,2,4-triazol-1-yl]-N-(4-phenylbutyl)- Usage And Synthesis |
| Description | YQ456 is a novel potent and selective inhibitor of myoferlin (MYOF inhibitor), which attenuates colorectal cancer progression. YQ456 showed high binding affinity to MYOF (KD = 37 nM) and excellent anti-invasion capability (IC50 = 110 nM). YQ456 was reported for the first time to interfere with the interactions between MYOF and Ras-associated binding (Rab) proteins at low nanomolar levels. This interference disrupted several vesicle trafficking processes, including lysosomal degradation, exosome secretion, and mitochondrial dynamics. Further, YQ456 exhibited excellent inhibitory effects on the growth and invasiveness of colorectal cancer. As the first attempt, the anticancer efficacy of YQ456 in the patient-derived xenograft (PDX) mouse model indicated that targeting MYOF may serve as a novel and practical therapeutic approach for colorectal cancer. |
| | Benzamide, 3-[3-ethyl-5-(4-methoxyphenyl)-1H-1,2,4-triazol-1-yl]-N-(4-phenylbutyl)- Preparation Products And Raw materials |
|